Skip to Main Content

Paper Details

First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial.
1
2023
Cancer, HER2, Patients, Regorafenib, Solid Tumours, acute kidney injury, adenocarcinoma, advanced oesophageal, gastric, or gastro-oesophageal junction cancer, advanced oesophagogastric (oesophageal, gastric, or gastro-oesophageal junction) adenocarcinoma, advanced oesophagogastric adenocarcinoma, anaemia, dry skin, fatigue, fluorouracil, gastric perforation, hepatotoxicity, hypertension, leucovorin, men, metastatic oesophagogastric, metastatic oesophagogastric cancer, nausea, neutrophil, nivolumab, oxaliplatin, participants, patient, patients, pruritus, rash, regorafenib, sepsis, women
Author NameAffiliation
Michael F BergerMarie-Josee & Henry R Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
  • 1 - 1

Datasets

Release 1.2